ANXA2
ATC code L01
AUNP12
Abagovomab
Abemaciclib
Abituzumab
Abrilumab
Acalabrutinib
Adagrasib
Adalimumab
Adecatumumab
Adipotide
Afatinib
Afelimomab
Aflibercept
Alectinib
Alemtuzumab
Alexion Pharmaceuticals
Alpelisib
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anastrozole
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Andecaliximab
Andexanet alfa
Anifrolumab
Anrukinzumab
Antigen
Antineoplastic
Apolizumab
Asciminib
Ascrinvacumab
Aselizumab
Asfotase alfa
AstraZeneca
Astra AB
Atenolol
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Avapritinib
Avdoralimab
Avelumab
Axatilimab
Axitinib
BMS-202
BMS-986189
BRAF (gene)
Balstilimab
Baricitinib
Basiliximab
Bavituximab
Bcr-abl fusion protein
Bectumomab
Belantamab mafodotin
Belimumab
Benralizumab
Bermekimab
Bertilimumab
Besilesomab
Bevacizumab
Bicalutamide
Biliary tract cancer
Bimekizumab
Binimetinib
Bivatuzumab mertansine
Bleselumab
Blinatumomab
Bosutinib
Botensilimab
Brazikumab
Breakthrough therapy
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Brompheniramine
Brontictuzumab
Bruton's tyrosine kinase
Budesonide
Budesonide/formoterol
Budesonide/glycopyrronium bromide/formoterol
C-Met
CA-170
CAS Registry Number
CD117
CD135
CD20
CD274
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Cambridge Antibody Technology
Camidanlumab tesirine
Camrelizumab
Canakinumab
Cancer immunotherapy
Candesartan
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carboplatin
Carlumab
Carotuximab
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Ceritinib
Certolizumab pegol
Cetuximab
ChemSpider
Chemical formula
Chimeric antibody
Cirmtuzumab
Cisplatin
Citatuzumab bogatox
Cixutumumab
Clazakizumab
Clenoliximab
ClinicalTrials.gov
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Conatumumab
Copanlisib
Cosibelimab
Crizanlizumab
Crizotinib
DNA vaccine
Dabrafenib
Dacetuzumab
Daclizumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Dapagliflozin
Daratumumab
Dasatinib
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Detumomab
Dinutuximab
Dinutuximab beta
Disufenton sodium
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug development
Drug nomenclature
Drugs.com
Duligotumab
Dupilumab
Durvalumab (data page)
Dusigitumab
Duvelisib
Duvortuxizumab
EML4
Ecromeximab
Eculizumab
Edrecolomab
Efalizumab
Eldelumab
Elotuzumab
Elranatamab
Elsilimomab
Emactuzumab
Emapalumab
Emibetuzumab
Encorafenib
Endometrial cancer
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
Epratuzumab
ErbB
Erdafitinib
Erlizumab
Erlotinib
Ertumaxomab
Esomeprazole
Etaracizumab
Etoposide
Etrolizumab
European Medicines Agency
Everolimus
Exenatide
Exotoxin
Faralimomab
Farletuzumab
Fedratinib
Fezakinumab
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
Flanvotumab
Fletikumab
Flotetuzumab
Fontolizumab
Food and Drug Administration
Fragment antigen-binding
Fresolimumab
Frexalimab
Fruquintinib
Fulvestrant
Fusion protein
Futibatinib
Futuximab
Galiximab
Ganitumab
Gavilimomab
Gefitinib
Gemcitabine
Gemtuzumab ozogamicin
Gevokizumab
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glofitamab
Glycopyrronium bromide/formoterol
Golimumab
Gomiliximab
Goserelin
Guide to Pharmacology
Guselkumab
HER2/neu
HPV
Hdl (identifier)
Head and neck cancer
Health Canada
Hedgehog signaling pathway
Human
Humanized antibody
Ianalumab
Ibalizumab
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Immune checkpoint
Immune system
Immunosuppression
Inavolisib
Indatuximab ravtansine
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Inebilizumab
Infigratinib
Infliximab
Inolimomab
Inotuzumab ozogamicin
Interleukin
Interleukin 2
Intetumumab
Intravenous therapy
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Isosorbide mononitrate
Istiratumab
Itolizumab
Ixekizumab
Janus kinase
KEGG
KN035
KRAS
Keliximab
Labetuzumab
Lampalizumab
Lanadelumab
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Lemalesomab
Lenvatinib
Lenzilumab
Lerdelimumab
Lesion
Lestaurtinib
Letolizumab
Leukemia
Lexatumumab
Lifastuzumab vedotin
Ligelizumab
Lilotomab
Lintuzumab
Lirentelimab
Lirilumab
List of withdrawn drugs
Live attenuated influenza vaccine
Lokivetmab
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Louis Schweitzer (CEO)
Lucatumumab
Lulizumab pegol
Lumiliximab
Lumretuzumab
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Mapatumumab
Margetuximab
Masitinib
Maslimomab
Matuzumab
Mavrilimumab
MedImmune
MedlinePlus
Mepolizumab
Metelimumab
Metoprolol
Midostaurin
Milatuzumab
Minretumomab
Mirikizumab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibodies
Monoclonal antibody
Monoclonal antibody therapy
Morolimumab
Mosunetuzumab
Motavizumab
Moxetumomab pasudotox
Myeloid
Nacolomab tafenatox
Namilumab
Naptumomab estafenatox
Narnatumab
Natalizumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nerelimomab
Nesvacumab
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Nivolumab/relatlimab
Non-receptor tyrosine kinase
Non-small cell lung cancer
Obinutuzumab
Ocaratuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Olaparib
Olaratumab
Oleclumab
Olmutinib
Olokizumab
Omalizumab
Omeprazole
Onartuzumab
Ontamalimab
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otelixizumab
Otlertuzumab
Oxelumab
Oxfordâ€“AstraZeneca COVID-19 vaccine
Ozoralizumab
PD-1
PD-1 and PD-L1 inhibitors
PD-L1
PMC (identifier)
PMID (identifier)
PRO 140
Paclitaxel
Pacritinib
Palbociclib
Palivizumab
Pamrevlumab
Panitumumab
Parsaclisib
Parsatuzumab
Pascolizumab
Pateclizumab
Patritumab
Pazopanib
Pembrolizumab
Pemigatinib
Pemtumomab
Perakizumab
Pertuzumab
Pexelizumab
Pexidartinib
Phases of clinical research
Pi3K inhibitor
Pidilizumab
Pinatuzumab vedotin
Pirtobrutinib
Placulumab
Platelet-derived growth factor receptor
Plozalizumab
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Priliximab
Pritumumab
Proapoptotic
Programmed cell death protein 1
Programmed death-ligand 1
Prohibitin
Prolgolimab
Propofol
Protein Data Bank
PubChem
Public domain
Quetiapine
Quilizumab
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radotinib
Radretumab
Ramucirumab
Ravulizumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Relatlimab
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Risankizumab
Rituximab
Robatumumab
Rociletinib
Roflumilast
Rontalizumab
Rosmantuzumab
Rosuvastatin
Route of administration
Rovalpituzumab tesirine
Rovelizumab
Roxadustat
Rozanolixizumab
Ruplizumab
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Salbutamol/budesonide
Samalizumab
Sarilumab
Satralizumab
Savolitinib
Saxagliptin
Sebelipase alfa
Secukinumab
Selpercatinib